An experimental drug used in COVID-19 treatment could slow respiratory distress syndrome, improve oxygen delivery to patients

An experimental COVID drug has been approved by the Food and Drug Administration for use in treating patients with respiratory distress.The drug, a novel version of COVID agent known as rivastigmine, is a new treatment for patients with severe COPD and other respiratory diseases, including severe asthma and COPD-related respiratory distress, the FDA said Monday.The […]